Investors Face August Deadline in Erasca Securities Class Action

The legal action, initiated by Levi & Korsinsky, LLP, centers on allegations that Erasca misled shareholders regarding its ERAS-0015 drug candidate. Throughout the class period, the company repeatedly compared the drug to Revolution Medicines’ RMC-6236, claiming superior binding affinity and efficacy at significantly lower doses. These assertions allegedly concealed critical intellectual property risks and the limitations of comparing the drugs without head-to-head clinical data.

Market confidence evaporated on April 27, 2026, when the company issued two corrective disclosures. The first revealed a patent infringement and trade secret misappropriation letter from RevMed. The second, released after market hours, disclosed a Grade 5 patient death in Phase 1 trials and acknowledged that previous performance comparisons lacked scientific validity. The stock price dropped from $21.49 to $9.90, wiping out over half of its value in a single day. Investors who suffered losses during this period are encouraged to contact the firm to review their eligibility for recovery, as the lawsuit proceeds on a contingency basis with no upfront costs for participants.